» Articles » PMID: 16987831

Pathophysiology and Clinical Consequences of Raynaud's Phenomenon Related to Systemic Sclerosis

Overview
Specialty Rheumatology
Date 2006 Sep 22
PMID 16987831
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

According to the so-called vascular hypothesis, Raynaud's phenomenon (RP) is one initial event in the pathophysiological cascade leading to sclerosis in systemic sclerosis (SSc). It is characterized by recurrent, reversible spasms of small arterioles and digital arteries, usually triggered by cold and emotional stress. Clinical signs of RP are a sudden pallor of single digits of fingers followed by reactive hyperaemia and in severe cases also by cyanosis. Besides imbalances between vasoconstrictive and vasodilatory processes, structural alterations of the involved vessels are fundamental to secondary RP in SSc. The latter is the reason why secondary RP in SSc, in contrast to primary RP, often leads to ischaemia and re-perfusion injuries. New insights into the pathophysiology of RP feature a special role for alpha2c-adrenoreceptors, Rho-kinase signalling pathways and soluble mediators. They have resulted in promising therapeutic options, including antagonism of endothelin receptors, inhibition of phosphodiesterases or selective blockade of alpha2c-adrenoreceptors. They should also have a positive impact on the course of SSc in general.

Citing Articles

Could Gas6/TAM Axis Provide Valuable Insights into the Pathogenesis of Systemic Sclerosis?.

Apostolo D, DOnghia D, Nerviani A, Ghirardi G, Sola D, Perazzi M Curr Issues Mol Biol. 2024; 46(7):7486-7504.

PMID: 39057085 PMC: 11275301. DOI: 10.3390/cimb46070444.


The effect of silver fibre gloves on Raynaud's phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial.

Liem S, Hoekstra E, Bonte-Mineur F, Checa C, Schouffoer A, Allaart C Rheumatology (Oxford). 2022; 62(SI):SI74-SI81.

PMID: 35441683 PMC: 9910564. DOI: 10.1093/rheumatology/keac243.


Is axillary botulinum toxin efficient in controlling secondary Raynaud's phenomenon? A case report.

DeMasters D, Sturgill E, Bartholomew A J Scleroderma Relat Disord. 2022; 6(3):327-329.

PMID: 35387220 PMC: 8922664. DOI: 10.1177/23971983211034077.


Distinct Metalloproteinase Expression and Functions in Systemic Sclerosis and Fibrosis: What We Know and the Potential for Intervention.

Leong E, Bezuhly M, Marshall J Front Physiol. 2021; 12:727451.

PMID: 34512395 PMC: 8432940. DOI: 10.3389/fphys.2021.727451.


Broadening our understanding of genetic risk for scleroderma/systemic sclerosis by querying the chromatin architecture surrounding the risk haplotypes.

Poppenberg K, Tutino V, Tarbell E, Jarvis J BMC Med Genomics. 2021; 14(1):114.

PMID: 33894768 PMC: 8066847. DOI: 10.1186/s12920-021-00964-5.